Market Overview

UPDATE: Goldman Sachs Initiates HeartWare International with Neutral

Share:
Related HTWR
Credit Suisse: Keep An Eye On These 6 Healthcare Stocks In 2015
AngioDynamics Q4 Earnings Beat, Revenues Up on Higher Sales
Sunshine Heart: There Is A Silver Lining To Those Clouds (Seeking Alpha)

Goldman Sachs initiated coverage on HeartWare International (NASDAQ: HTWR) with a Neutral rating and a price target of $93.

Goldman Sachs noted, "We initiate on shares of HeartWare (HTWR) with a Neutral rating and 12-month price target of $93, implying 4.1% upside from current levels. Over the long term, the company has the potential to drive accelerating revenue growth for multiple years as the LVAD market continues to develop due to increased utilization and technological advances. That said, HeartWare's entrance into the US market may be more difficult than expected and we see consensus sales estimates as too high. HeartWare, pending approval, will only have access to the slower and more penetrated Bridge-to-Transplant market, making near-term growth almost entirely dependent on shares gains. "

HeartWare International closed at $89.68 on Thursday.

Latest Ratings for HTWR

DateFirmActionFromTo
Feb 2015Canaccord GenuityMaintainsBuy
Feb 2015Leerink SwannMaintainsOutperform
Feb 2015JP MorganMaintainsOverweight

View More Analyst Ratings for HTWR
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (HTWR)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→